TAA

Opening Remarks

甘良生 理事長 Lawrence Gan, Ph.D
Director of Taiwan Antibody Association; President/CEO, Foresee Pharmaceuticals

紀威光 副執行長 Wei-kuang Chi, Ph.D.
Vice President, Development Center for Biotechnology

Chimeric Antigen Receptor T Cells (CAR-T)

Moderator：官建村 博士 Chien-Tsun Kuan, Ph.D.
EVP/ COO & CTO, GenomeFrontier Therapeutics, Inc.

Keynote Speaker

Bryan D. Choi, MD, PhD
Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA / Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

CAR-T Cell Therapy for B-cell malignancies

張裕享 醫師 Yu-Hsiang Chang, MD, Ph.D.
Tai Chen Stem Cell Therapy Center, National Taiwan University Hospital

Multiple carcinoma targetable CAR for immune cell therapy

邱紹智 博士 Shao Chih Chiu, Ph.D.
Graduate Institute of Biomedical Sciences, China Medical University, Center for Cell Therapy, China Medical University Hospital

Antibody-drug conjugates (ADC)

Moderator：劉理成 總經理 Lee Cheng Liu, Ph.D.
President/CEO, EirGenix Inc.

賴明添 博士 Ming-Tain Lai, Ph.D.
Chief Scientific Officer, OBI Pharma, Inc.

Site-specific trimannosyl conjugation and ADC capability in DCB

莊士賢 博士 Simon Shih-Hsien Chuang, Ph.D.
Director, Development Center for Biotechnology, Medicinal Chemistry Department, Institute of Pharmaceutics

Immuno-Oncology (IO)

Moderator：吳忠勳 執行長 Chung-Hsiun Herbert Wu, Ph.D.
CEO, Development Center for Biotechnology

Tumor localized immunotherapy

藍耿立 醫師 Keng-Li Lan, M.D., Ph.D.
Associate Professor, Institute of Traditional Medicine, School of Medicine, National Yang-Ming University; Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital

Keynote Speaker

Engineering cancer immunotherapy

Cheng-I Wang, Ph.D.
Head of the human monoclonal antibody technology platform, Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR)